MUCL1

MUCL1 is a small secreted glycoprotein that functions as an oncogenic signaling mediator by activating β-catenin, NF-κB, and PI3K/AKT pathways to promote cell proliferation, invasion, migration, and epithelial-mesenchymal transition (PMID:35059735, PMID:37477531, PMID:41770679). MUCL1 protein stability is regulated post-translationally by ST3GAL1-mediated sialylation, which increases its half-life, and by UCHL1-mediated deubiquitination, which prevents its proteasomal degradation (PMID:41770470, PMID:41770679). MUCL1 also physically interacts with the phosphatase DUSP16 to activate AMPK signaling and confer paclitaxel resistance in breast cancer cells (PMID:41181635).

1. 2021 Low

   Initial expression analyses linked MUCL1 to melanogenesis regulation, raising the question of whether MUCL1 has functional roles beyond its identity as a breast-specific marker.

   Evidence Microarray-based correlation of MUCL1 expression with melanin pathway genes in melanocytes and melanoma cells

   PMID:34545566

   Open questions at the time

   • Largely correlative — no direct functional manipulation of MUCL1 in melanocytes was performed
   • Mechanistic link between MUCL1 and FOXO/autophagy signaling not validated
   • Not independently replicated
2. 2022 Medium

   Establishing that MUCL1 drives oncogenic signaling: knockdown revealed that MUCL1 activates β-catenin via Ser-552 phosphorylation and nuclear translocation, promoting proliferation, invasion, and EMT in colorectal cancer cells.

   Evidence siRNA knockdown in HT-29 and SW620 CRC cell lines with Western blotting, invasion/migration assays, colony formation assays

   PMID:35059735

   Open questions at the time

   • Upstream kinase mediating β-catenin Ser-552 phosphorylation downstream of MUCL1 not identified
   • In vivo validation in CRC models not performed
   • Single-lab observation
3. 2023 Medium

   The question of how MUCL1 expression is regulated was addressed by identifying miR-186-5p as a direct negative regulator of MUCL1 mRNA, with derepressed MUCL1 activating the PI3K/AKT pathway to drive breast cancer cell proliferation and invasion.

   Evidence miR-186-5p mimic/inhibitor transfection in MDA-MB-231 cells with PI3K activator rescue, Western blotting, and functional assays

   PMID:37477531

   Open questions at the time

   • Direct luciferase reporter validation of miR-186-5p binding to MUCL1 3′-UTR not reported in this discovery
   • In vivo relevance of miR-186-5p–MUCL1 axis not tested
   • Mechanism linking MUCL1 protein to PI3K activation unknown
4. 2025 Medium

   MUCL1 was shown to physically interact with DUSP16 and upregulate its expression, activating AMPK signaling and conferring paclitaxel resistance — establishing a chemoresistance mechanism through a MUCL1–phosphatase axis.

   Evidence MUCL1 overexpression/knockdown in breast cancer cell lines with AMPK activator rescue, Western blotting, apoptosis assays

   PMID:41181635

   Open questions at the time

   • Binding interface between MUCL1 and DUSP16 not mapped
   • Whether DUSP16 phosphatase activity is required for the AMPK activation is untested
   • In vivo chemoresistance validation not performed
5. 2026 High

   Two complementary studies resolved how MUCL1 protein stability is maintained: ST3GAL1-mediated sialylation and UCHL1-mediated deubiquitination each independently stabilize MUCL1, with functional consequences for tumor growth/metastasis and endothelial inflammation, respectively.

   Evidence Co-IP, sialylation assays, sialyltransferase inhibitor, in vivo xenograft/metastasis models (ST3GAL1 study); Co-IP, ubiquitination assay, CHX chase, siRNA rescue in LPS-treated HUVECs (UCHL1 study)

   PMID:41770470 PMID:41770679

   Open questions at the time

   • Specific sialylation sites on MUCL1 not mapped
   • Whether sialylation and deubiquitination are coordinated or independent regulatory events is unknown
   • Structural basis of UCHL1–MUCL1 interaction not determined

• The direct biochemical mechanism by which MUCL1 activates β-catenin, PI3K/AKT, and AMPK signaling — whether through receptor engagement, scaffolding, or another mode — remains undefined.
• No receptor or direct binding partner on the cell surface identified for MUCL1 signaling initiation
• No structural model of MUCL1 exists
• Physiological (non-cancer) function of MUCL1 is largely uncharacterized